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S 47445 is a positive allosteric modulator of glutamate AMPA-type receptors that possesses 
procognitive, neurotrophic and enhancing synaptic plasticity properties. Its chronic 
administration promotes antidepressant- and anxiolytic-like effects in different rodent models 
of depression. 
We have evaluated the behavioral effects of S 47445 in the bilateral olfactory bulbectomy 
mice model (OB) and the adaptive changes in those proteins associated to brain 
neuroplasticity (BDNF and mTOR pathway). Following OB surgery, adult C57BL/6J male 
mice were chronically administered S 47445 (1, 3 and 10 mg/kg/day; i.p.) and fluoxetine (18 
mg/kg/day; i.p.), and then behaviorally tested in the open field test. Afterwards, the 
expression levels of BDNF, mTOR, phospho-mTOR, 4EBP1 and phospho-4EBP1 were 
evaluated in hippocampus and prefrontal cortex. 
Both drugs reduced the OB-induced locomotor activity, a predictive outcome of 
antidepressant efficacy, with a similar temporal pattern of action. S 47445, but not fluoxetine, 
showed an anxiolytic effect as reflected by an increased central activity. Chronic 
administration of S 47445 reversed OB-induced changes in BDNF and phopho-mTOR 
expression in hippocampus but not in prefrontal cortex. 
The chronic administration of S 47445 induced antidepressant- and anxiolytic-like effects at 
low-medium doses (1 and 3 mg/kg/day, i.p.) associated with the reversal of OB-induced 





















 S 47445 is an AMPA positive allosteric modulator. 
 S 47445 has antidepressant- like effects in olfactory bulbectomized mice. 
 S 47445 has anxiolytic- like effects in the olfactory bulbectomized mice. 
 S 47445 modulates BDNF and mTOR in prefrontal cortex of bulbectomized mice. 
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Major depression is a disorder with a high prevalence, and severe health and socioeconomic 
consequences (Kessler et al., 2003). Although a great effort has been done to unravel the 
molecular basis of the disease to develop more effective treatments, the currently prescribed 
antidepressant drugs present important limitations as the low rates of treatment response 
(Trivedi et al., 2006). 
In the last years, new therapeutic strategies targeting BDNF and/or mTOR signaling pathways 
have been proposed since dysfunction of these neuroplasticity pathways have been linked to 
various psychiatric phenotypes, and clinically used antidepressants may require such 
signaling pathways to exert their therapeutic actions (Autry and Monteggia, 2012; Pilar-
Cuéllar et al., 2013; Abelaira et al., 2014). Recently, these neuroplasticity-related actions have 
been also associated with the antidepressant effect of non-serotonergic compounds such as 
ketamine, a compound described as NR2B non-competitive NMDA antagonist that has 
demonstrated to induce effective and rapid effects at sub-anesthetic doses in clinical trials and 
in some rodent models (Zarate et al., 2006; Sanacora et al., 2008). Interestingly, BDNF 
release and activation of the mTOR signaling pathways induced by ketamine seems to be 
dependent on glutamate-AMPA receptor activation notably by involving the metabolite, 
(2R,6R)-hydroxynorketamine, which seems to act  in a sustainable manner on AMPA 
receptors (Autry et al., 2001; Li et al., 2010; Lepack et al., 2014; Zanos et al., 2016). 
Positive AMPA receptor modulators (AMPA-PAMs) have the ability to enhance AMPA 
receptor function without direct receptor activation (Arai and Kessler, 2007). AMPA receptor 
potentiating drugs are reported to increase LTP, learning and memory, and BDNF (Bliss and 
Collingridge, 1993; Arai et al., 2000; Arai and Kessler, 2007). Besides their procognitive 
















some of them act in a synergistic action with antidepressant drugs (Bai et al., 2003; Alt et al., 
2005; O’Neill and Witkin, 2007; Damgaard et al., 2010). S 47445 (8-cyclopropyl-3-[2-(3-
fluorophenyl)ethyl]-7,8-dihydro-3H-[1,3]oxazino[6,5-g][1,2,3] benzotriazine-4, 9-dione) is a 
selective AMPA-PAM (Bretin et al., 2017; Giralt et al., 2017) that has demonstrated an 
antidepressant-like effect in the corticosterone mice model and in chronic mild stress (CMS) 
rat model, a fast-acting effect on anhedonia, as well as an anxiolytic profile in different 
behavioral tests (Mendez-David et al., 2017). 
Among the animal models that resemble a depression-like state with comorbid anxiety, the 
bilateral olfactory bulbectomy (OB), a recognized animal model of agitated 
hyposerotoninergic depression (Lumia et al., 1992; Wang et al., 2007), has been widely used 
for preclinical research in rodents. This model presents similarities of some of the behavioral, 
neurochemical, neuroendocrine and immunological changes, with those observed in 
depressive patients (Kelly et al., 1997; Song and Leonard, 2005). Olfactory bulbectomy leads 
to a typical hyperactive phenotype, increased exploratory behavior and also memory and 
learning deficits (Tadano et al., 2004; Zueger et al., 2005) that can be measured using some 
simple behavioral tests, thus allowing the characterization of the emotional and cognitive state 
of the animals. The chronic, but not acute, administration of clinically effective antidepressant 
drugs in OB animals reverse most of the behavioral, neurochemical and structural 
disturbances exhibited by OB animals (Song and Leonard, 2005; Jarosik et al., 2007; Sato et 
al., 2008), therefore representing an interesting tool for pharmacological research (Linge et 
al., 2016). Indeed, the reversal of OB-induced locomotor hyperactivity is considered a 
behavioral outcome for assessing antidepressant efficacy (Kelly et al., 1997; Song and 
Leonard, 2005). 
Here we present the evaluation of the effect of the AMPA-PAM S 47445 in the olfactory 
















fluoxetine. In addition, we have evaluated the implication of the neurotrophic factor BDNF, 
and the mTOR pathway. 
 
2. METHODS 
2.1. Animals and OB surgery 
Animals used were 2-3 month old male C57BL/6J mice weighing 25–30 g. All procedures 
were carried out with the previous approval of the Animal Care Committee of the University 
of Cantabria and according to the Spanish legislation (RD 53/2013) and the European 
Communities Council Directive (2010/63/UE) on “Protection of Animals Used in 
Experimental and Other Scientific Purposes. Animals were individually housed, in climate 
controlled rooms with 12 h light–12 h dark cycle, and provided with food and water ad 
libitum. 
The OB and sham-operation (sham) procedure was performed as previously described (Linge 
et al., 2013; 2016). Mice were anesthetized with isoflurane (2%; Schering Plough, United 
Kingdom) to perform the bilateral olfactory bulbectomy. In brief, a midline sagital incision 
was made in the skin overlying the skull, and a burr hole was drilled through which both 
olfactory bulbs were bilaterally aspired using a suction pump. Finally, the hole was filled with 
bone wax to avoid bleeding. After bulbectomy/sham surgery, a four week period was waited 
for the animal recovery and the development of the OB syndrome before the initiation of drug 
treatment was confirmed by peripheral hyperactivity in the open field test. At the end of the 
study, animals were sacrificed and the lesions were verified to discard frontal pole lesions 
and/or incomplete removal of olfactory bulbs. Sham operations were done in the same way, 


















2.2. Drugs and treatments 
S 47445 (batch L 0041063) provided by Servier (Bretin et al., 2017) was administered at 1, 3 
or 10 mg/kg/day i.p. for 4 weeks. The vehicle of S 47445 used was (HEC 1% and Tween 1%, 
i.p.). Fluoxetine (18mg/kg/day) i.p. for 4 weeks, using saline as vehicle. Both treatments 
started 1 month after OB surgery. Drugs were administered at 12 a. m. Vehicle group 
corresponded to the vehicle of S 47445 since no difference was previously observed between 
HEC 1% and Tween 1%, i.p. and saline (Mendez-David et al., 2017). 
2.3. Behavioral testing: open field test (OF) 
We evaluated the drug (S 47445 or fluoxetine) effects on the OB-induced hyperactivity (to 
assess antidepressant-like effects) and central ambulation (to assess anxiolytic-like effects) 
(Linge et al., 2016). The open field test was performed during the light phase (between 8 and 
11 a. m.). Animals were transported to the experimental room 1 h before the start of the 
experiment to acclimatize, and 24 h after drug administration. The open field apparatus was a 
brightly lit (350 lx) white wooden box (50 cm × 50 cm × 30 cm) with white floor and bright 
walls. Mice were placed in the center of the apparatus for 5 min, and behavior was video-
tracked using a computerized system (Any-maze Video-Tracking software, Stoelting Co., 
U.S.A.). Total, peripheral and central distances travelled were measured. The total and 
peripheral distance and the percentage of distance travelled in the center (30 cm × 30 cm) 
were used to evaluate drugs effects. 
2.4. Western blot 
Animals were killed by decapitation, their brains removed, and the hippocampi and prefrontal 
cortices dissected and stored at −80 ºC. Each sample was homogenized and processed in order 
















homogenized (1:15, 500 µl approx.) using a Potter homogenizer in homogenization buffer (10 
mM Hepes, pH 7.9, 1.5 mM MgCl2, 10 mM KCl) containing protease and phosphatase 
inhibitors (1 mM PMSF, 10 µl/ml aprotinin, 10 µg/ml leupetin, 10 µg/ml pepstatin A, 10 
µg/ml antipain, 10 µg/ml chymostatin, 5 µg/ml trypsin inhibitor, 1 mM NaV, 1 mM NaF, 1 
mM cantharidin and 10 µM E-64). After homogenization, 250 µl of homogenate were lysated 
in lysis buffer (homogenization buffer containing 1% Igepal, 0.1% sodium deoxycholate, 
0.2% SDS and 0.1% Triton X-100) 30 min on ice and centrifuged at 14000 xg 10 min at 4ºC. 
The supernatant was aliquoted and conserved at -20ºC. Protein quantification was performed 
according to the Lowry method. 
Protein preparations (45 μg per lane) were resolved on 8.5% or 15% SDS-PAGE gel 
electrophoresis and transferred to polyvinylidene difluoride (PVDF; non-phosphorylated 
proteins) or to nitrocellulose (phosphorylated proteins) membranes. Non-specific binding sites 
were blocked with 5% non-fat dry milk in TBS-T buffer (20 mM Tris, pH 7.2, 150 mM NaCl, 
and 0.05% Tween) for 60 minutes at room temperature. Membranes for determination of 
phosphorylated proteins were blocked in 3% non-fat dry milk in TBS-T buffer plus 1 mM 
sodium vanadate and 1 mM sodium fluoride. These membranes were incubated in rabbit anti-
BDNF (1:500) from Santa Cruz Biotechnology, Inc. (USA); rabbit anti-mTOR (1:1000) and 
mouse anti-β-tubulin (1:20000) from Sigma-Aldrich (Spain); and rabbit anti-phospho-mTOR 
(1:500), rabbit anti-4EBP1 (1:500), rabbit anti-phospho-4EBP1 (1:500) from Cell Signaling 
Technology, Inc. (USA), overnight. After extensive washings in TBS-T (TBS, 0.05% Tween 
20) membranes were incubated with horseradish peroxidase conjugated secondary antibodies. 
Specific signal was detected using ECL Advance kit (GE Healthcare Europe GmbH, Munich, 
Germany). Blots quantitation was performed by densitometric analysis using Scion Image 
Software. The densitometry values were normalized with respect to β-tubulin. Those values 

















2.5. Statistical analysis 
All the values are expressed as mean ± standard error of mean (S.E.M). The data were 
statistically analyzed by a Student´s t-test or one-way ANOVA followed by a Student-
Newman-Keuls posthoc test where appropriate. GraphPad Prism 5.01 (San Diego, CA, USA) 
was used for the statistical analysis. A p value < 0.05 was considered significant. 
 
3. RESULTS AND STATISTICAL ANALYSES 
3.1. Chronic S 47445 reverted OB-induced hyperactivity and anxiety 
In this study, we have used the OB model of depression in C57BL/6J mice. OB-induced 
syndrome was confirmed 28 days post-surgery, and before the initiation of the chronic 
treatment with S 47445 (1, 3 and 10 mg/kg/day) and fluoxetine (18 mg/kg/day) (Figure 1). 
 
 
Figure 1. Experimental design. Time-line schedule for the olfactory bulbectomy and the 
behavioral testing. OB: olfactory bulbectomy; OF: open field test. 
 
The typical locomotor hyperactivity of OB mice was evidenced by an increased total distance 
travelled (+105 % vs sham group, t=7.663, df=63, p < 0.001, Figure 2A, t=0), and an increase 
















2B, t=0). The OB-induced enhanced anxiety behavior was evidenced by a reduced central 
activity (-52 % vs sham group, t=6.906, df=63 p < 0.001, Figure 2C, t=0). The different 
groups of OB mice used for the drug treatments showed a similar OB-induced behavioral 
phenotype. 
The behavioral effects of the chronic treatment with S 47445 (1, 3 and 10 mg/kg/day doses) 
and fluoxetine (18 mg/kg/day) were evaluated following 7, 21 and 28 days of administration. 
Regarding the total locomotor activity, a one-way ANOVA revealed an effect of treatment at 
21-day (F(4,46)=3,256, p = 0,020) and 28-day (F(4,45)=4,658, p = 0,003) time points. Post-hoc 
analysis showed that treatment with S 47445 significantly reverted OB-induced hyperactivity 
after 28 days of treatment (1 mg/kg/day: -25 % vs OB-veh, p < 0.05; 3 mg/kg/day: -30 % vs 
OB-veh, p < 0.05). Chronic fluoxetine at the 18 mg/kg/day dose reduced total activity in OB 
































Figure 2. Effect of chronic administration of S 47445 and fluoxetine in OB mice in the 
open field test at different time points. Total distance travelled (A), peripheral 
deambulation (B) and percentage of central distance versus total (C). OB: olfactory 
bulbectomy mice; OB-flx corresponds to the OB mice treated with fluoxetine at the dose 
of 18 mg/kg/day, i.p.; OB-s1, s3 and s10 correspond to the OB mice treated with S 47445 
at the doses of 1, 3 and 10mg/kg, i.p. respectively. Data are mean ± SEM. ### p < 0.001 vs 
sham group (Student’s t-test). * p < 0.05 and ** p < 0.01 vs OB-veh group (one-way 
ANOVA followed by Newman-Keuls post hoc test). n=10-11 animals per group. 
 
The analysis of the peripheral distance travelled using a one-way ANOVA revealed an effect 
of treatment following 21 days (F(4,46)=3.369, p = 0.017) and 28 days (F(4,45)=4.888, p = 0.002) 
of administration. Post-hoc analysis showed that treatment with S 47445 significantly 
reverted OB-induced peripheral activity following 21 days (1 mg/kg/day: -23 % vs OB-veh, p 
< 0.05; 3 mg/kg/day: -19 % vs OB-veh, p < 0.05; 10 mg/kg/day: -15 % vs OB-veh, p < 0.05 ), 
and 28 days (1 mg/kg/day: -27 % vs OB-veh, p < 0.05; 3 mg/kg/day:-31 % vs OB-veh, p < 
0.05) of administration. Chronic fluoxetine at the 18 mg/kg/day dose reduced peripheral 
activity in OB mice (21-days: -23 % vs OB-veh, p < 0.05; 28-days: -34 % vs OB-veh, p < 
0.01) with a similar magnitude and temporal fashion than S 47445 (Figure 2B). 
Regarding central activity, one-way analysis revealed a significant effect after 7-days 
(F(4,49)=7.031, p < 0.001) and 21-days (F(4,46)=10.55, p < 0.001) of treatment. Post-hoc 
analysis showed that treatment with S 47445 significantly increased open field central activity 
in OB mice following 7 days (1 mg/kg/day: +90 % vs OB-veh, p < 0.01; 3 mg/kg/day: +73 % 
















+49 % vs OB-veh, p < 0.01) of treatment. However, fluoxetine treatment was devoid of any 
effect at all the time-points studied (Figure 2C). 
3.2. BDNF in OB-mice: effect of S 47445 versus fluoxetine 
The levels of mature BDNF, corresponding to the active form of the protein, were measured 
in the hippocampal and prefrontal cortex lysates from OB mice, and the effect of 4-week 
treatment with one active dose of S 47445 showing behavioral efficacy (3 mg/kg/day) and in 
comparison to fluoxetine (18 mg/kg/day) was evaluated. The olfactory bulbectomy tended to 
increase BDNF protein expression (+57 % vs sham-veh, t=1.349, df=18, p = 0.19, Student´s t 
test) in the hippocampus. A significant effect of drug treatment on BDNF protein expression 
was detected in this area in OB mice (F(2,23) = 4.395, p = 0.024, one-way ANOVA). Chronic S 
47445 significantly decreased hippocampal BDNF protein expression (-78 % vs OB-veh, p < 
0.05) whereas chronic fluoxetine did not induce any significant change (- 1.4 % vs OB-veh) 
(Figure 3A). 
The olfactory bulbectomy model did not induced any modification of the BDNF protein 
expression in prefrontal cortex. Drug treatments in this model did not present significant 
effect on BDNF protein expression, although a clear tendency was observed (F (2,17) = 2.862, p 


















Figure 3. Expression of BDNF protein in hippocampus (A) and prefrontal cortex (B) from OB 
mice and the effect of chronic treatment (4 weeks) with S 47445 (3 mg/kg/day, i.p.) in 
comparison with fluoxetine (18 mg/kg/day, i.p.). Values represent mean ± SEM. Sham-veh, 
sham-operated mice treated with vehicle; OB-veh, OB-vehicle-treated; OB-flx, OB-
fluoxetine-treated; OB-s3, OB mice treated with S 47445 at 3 mg/kg/day. * p < 0.05 vs OB-
vehicle, and # p < 0.05 vs OB-fluoxetine; one-way ANOVA followed by Newman-Keuls post 
hoc test. n=7-10 animals per experimental group in duplicate for each sample. 
 
3.3. mTOR signaling in OB mice: effect of S 47445 versus fluoxetine 
We have evaluated the mTOR complex 1 signaling, since it has been described that ketamine 
antidepressant-like effects are dependent on the activation of this pathway (Li et al., 2010). 
Levels of mTOR signaling pathway proteins (mTOR/p-mTOR and 4RBP1/p-4EBP1) were 
















S 47445 (3 mg/kg/day) versus fluoxetine (18 mg/kg/day) was evaluated. We did not detect 
significant changes in the expression of mTOR in OB-vehicle treated mice in comparison 
with sham-vehicle treated counterparts (-13 % in OB-veh vs sham-veh; t=0.920, df=13, p = 
0.37, Student´s t test). Moreover, drug treatments did not modify the amount of mTOR 
protein in the hippocampus of OB mice (-1.3 % and +4.5% vs OB-veh for OB-flx and OB-s3, 
respectively; F(2,17) = 0.100, p=0.905, one-way ANOVA) (Figure 4A). 
 
 
Figure 4. Expression of mTOR and p-mTOR, and 4EBP1 and p-4EBP1 in hippocampal total 
















mg/kg/day, i.p.) in comparison with fluoxetine (18 mg/kg/day, i.p.). A) mTOR protein, B) p-
mTOR protein, C) p-mTOR/mTOR ratio, D) 4EBP1, E) p-4EBP1 and F) p-4EBP1/4EBP1 
ratio. Values represent mean±S.E.M. Sham-veh, sham-operated mice treated with vehicle; 
OB-veh, OB-vehicle-treated; OB-flx, OB-fluoxetine-treated; OB-s3, OB mice treated with S 
47445. * p < 0.05 vs OB-vehicle, and # p < 0.05 vs OB-fluoxetine; one-way ANOVA 
followed by Newman-Keuls post hoc test. n = 6-8 animals per experimental group in 
duplicate for each sample. 
 
Regarding the expression of the functional mTOR protein (the phosphorylated mTOR, p-
mTOR), OB surgery induced a trend to increased p-mTOR expression (+44% vs sham-veh; 
t=1.566, df=13, p = 0.14, Student´s t test). In contrast to fluoxetine, S 47445 decreased, 
though not significantly, p-mTOR expression in OB mice (+12% and -41% vs OB-veh for 
OB-flx and OB-s3, respectively; F(2,18) = 3.297, p = 0.060, one-way ANOVA) (Figure 4B). 
As shown in Figure 4C, OB induced a non-significant increase in the p-mTOR/mTOR ratio 
(+45 % vs sham-veh; t=1.310, df=13, p = 0.21, Student’s t test). Chronic treatment with S 
47445 or fluoxetine did not induce changes in the p-mTOR/mTOR ratio compared to the OB-
vehicle group, although a tendency to a decrease was detected in the S 47445 group (+4,8% 
and -42% vs OB-veh for OB-flx and OB-s3, respectively; F(2,18)=2.465, p = 0.113, one-way 
ANOVA).  
The olfactory bulbectomy (Figure 4D) did not alter the expression of total 4EBP1 protein 
(+11% vs sham-veh; t=0.596, df=17, p = 0.56, Student´s t test). Following the chronic 
treatments with S 47445 and fluoxetine, an increase in the amount of 4EBP1 protein 
expression in the hippocampus of OB mice was detected (+76% and +47% vs OB-veh for 
















As shown in Figure 4E, OB surgery tended to increase the expression of the p-4EBP1 (+44% 
vs sham-veh; t=2.020, df=17, p = 0.06, Student´s t test). One-way analysis revealed a 
significant effect of treatment (F(2,25) = 4.654, p = 0.019). Post-hoc analysis showed that 
treatment with S 47445 significantly increased the expression of p-4EBP1 protein in the 
hippocampus of OB mice (+222% vs OB-veh, p < 0.05) in comparison with fluoxetine (+21% 
vs OB-veh, ns), and was significantly different from the effect of fluoxetine in OB mice (p < 
0.05, OB-3s vs OB-flx). 
Regarding the ratio between functional (phosphorylated) 4EBP1 protein vs total 4EBP1 
expression (p-4EBP1/4EBP1) (Figure 4F), no significant changes were observed following 
OB surgery (+35% vs sham-veh; t=1.503, df=17, p = 0.15, Student´s t test). Chronic treatment 
with fluoxetine or S 47445 did not induce significant changes in the p-4EBP1/4EBP1 ratio 
when compared to the OB-vehicle group value, although a tendency to a decrease was 
detected in the OB-fluoxetine group (-44% and +4.3% and vs OB-veh for OB-flx and OB-s3, 


















Figure 5. Expression of mTOR and p-mTOR, and 4EBP1 and p-4EBP1 in prefrontal cortex of 
OB mice and the effect of chronic treatment (4 weeks) with S 47445 (3 mg/kg/day, i.p.) in 
comparison with fluoxetine (18 mg/kg/day, i.p.). A) mTOR protein, B) p-mTOR protein, and 
C) p-mTOR/mTOR ratio. Values represent mean±S.E.M. Sham-veh, sham-operated mice 
treated with vehicle; OB-veh, OB-vehicle-treated; OB-flx, OB-fluoxetine-treated; OB-s3, OB 
mice treated with S 47445. n = 6-8 animals per experimental group in duplicate for each 
sample. 
 
The mTOR signalling pathway was also evaluated in the prefrontal cortex. No significant 
differences were obtained in the total or activated mTOR protein in the olfactory bulbectomy 
model of depression, nor after the chronic treatment with fluoxetine or the compound S 47445 
(Figures 5A, B and C). 
 
4. DISCUSSION 
Our results demonstrate the behavioral effects of S 47445 in an animal model that possesses a 
predictive validity. Indeed, most of the clinically effective antidepressants reverse many of the 
behavioral, neurochemical and structural disturbances exhibited by OB animals (Cryan et al., 
1998; Song and Leonard, 2005; Jarosik et al., 2007; Sato et al., 2008). Locomotor 
hyperactivity is a core manifestation of OB animals since the olfactory bulbs belong to the 
limbic system and their removal affects extensive efferent networks including the striatum, 
which explain the impact of the olfactory bulbectomy on locomotor function (Song and 
Leonard, 2005). In our study, the chronic treatment with low-mild doses of S 47445 (1 and 3 
















mice exhibit when exposed to a brightly illuminated open field, a behavioral readout 
considered to reflect antidepressant efficacy (Kelly et al., 1997; Song and Leonard, 2005).   
In our study, the reduction of hyperactivity elicited by the chronic administration of the 
compound S 47445 was similar to the SSRI antidepressant fluoxetine in the OB mouse model, 
and in good agreement with previous studies assessing clinically effective antidepressants in 
bulbectomized mice (Machado et al., 2012; Freitas et al., 2013), or in rats (Kelly et al., 1997; 
Song and Leonard, 2005; Rodríguez-Gaztelumendi et al., 2009). The choice of comparison of 
the effect of the drug with a current therapy (fluoxetine) was done in order to be more relevant 
for a future clinical use in Major Depressive patients. The antidepressant effect of S 47445 
seems to be disease-dependent since this compound does not induce any impact on normal 
behavior as no changes in locomotor activity (Bretin et al., 2017), nor in general behavior 
over a dose range of 3 to 100 mg/kg in control mice (Bretin et al., 2018) were observed. 
Regarding the antidepressant effect of fluoxetine, we have already reported a decrease 
locomotor activity in OB mice, but a lack of changes in the total distance travelled in the open 
field test in their sham counterparts (Amigó et al., 2016). The antidepressant effect of S 47445 
is in good agreement with the findings reported in other rodent models of emotional behavior 
since this AMPA-PAM also reversed the depressive-like state induced by chronic 
corticosterone model or CMS at the same range of doses, and presented anxiolytic behavior 
without altering locomotor activity in chronically-treated corticosterone mice (Mendez-David 
et al., 2017). Moreover, enhancement of AMPA signaling has been reported to result in 
antidepressant-like effects by other AMPA-PAM like LY392098 (Farley et al., 2010) or 
ampakines (Knapp et al., 2002). These drugs were effective in reducing the depressive-like 
manifestations in mice subjected to the chronic unpredictable mild stress (CUMS) and in rats 
















Additionally, S 47445 had an early anxiolytic effect (after 7 and 21 days of treatment) on the 
attenuation of the enhanced anxiety response exhibited by OB mice, evidenced by an increase 
in central activity, together with reduced peripheral deambulation. However, the effect of S 
47445 on central activity showed no significant effect following 28 days of treatment. Though 
it deserves further investigation, these changes might be dependent on molecular 
modifications leading to receptor desensitization/tolerance phenomena. In the literature, there 
are some evidences against and in favor of the potential of AMPA-PAMs as anxiolytic drugs 
at different doses. S 47445 presented anxiolytic effects from 1 to 10 mg/kg/day after 4 weeks 
of treatment when assessed in the elevated plus maze, but only at 1 mg/kg/day in the open 
field test (Mendez-David et al., 2017). The AMPA receptor potentiator LY392098 exhibited 
an antidepressant but not anxiolytic effect in the CUMS in mice (Farley et al., 2010). In our 
study, the SSRI fluoxetine was devoid of any anxiolytic-like effect. However, it is worth to 
mention that this SSRI induces paradoxical responses in C57BL/6J mouse strain, with no 
effect in the splash test, and even increasing the anxiogenic-like responses in the novelty 
suppressed feeding test in the CUMS model (Gosselin et al., 2017). 
The higher efficacy of the low-mild doses of S 47445 (1 and 3 mg/kg/day) in decreasing the 
hyperactivity and anxious-like behavior contrasts with the lack of effect of the highest dose 
(10 mg/kg/day), since this dose was previously reported to be active in other emotional 
behavior models (corticosterone, CMS models or stress prenatal) (Bretin et al., 2016; 
Mendez-David et al., 2017). However, this pattern is quite similar to the biphasic and/or the 
U-shape dose-response described for the AMPA potentiators LY392098 (Li et al., 2001) in 
the FST paradigm in rats and mice.  
The chronic administration of S 47445 (3 mg/kg/day) significantly reversed the increased 
BDNF hippocampal expression associated to OB syndrome. In OB mice, hippocampal 
















levels are up-regulated, in line with our results. It is postulated that up-regulation of BDNF 
protein and other neuroplasticity proteins (i.e. pCREB and pERK) in the hippocampus of OB 
mice may represent an adaptive response to the model injury (Rodríguez-Gaztelumendi et al., 
2009; Hendriksen et al., 2015). However, it is noteworthy to mention that the OB model 
presents opposite changes in rat (Hendriksen et al., 2012) and mice (Hellweg et al., 2007). 
These species-dependent differences regarding neurochemical and molecular changes, also 
affect to the response to drugs (Hendriksen et al., 2015). There are some evidences about the 
modulation of hippocampal BDNF expression by AMPA signaling. The antidepressant-like 
activity of magnesium in the OB model is associated with the AMPA/BDNF pathway 
(Pochwat et al., 2015), and AMPA-PAMs are reported to increase mRNA expression of 
BDNF and TrkB in rat hippocampus in a dose-and time-dependent manner (Mackowiak et al., 
2002). Moreover, chronic treatment (2 weeks) with S 47445 was reported to increase or to 
reverse the decrease in both the mRNA and the protein levels of BDNF in the hippocampus of 
aged rats using procognitive and antidepressant active doses in rodents (Calabrese et al., 
2017; Mendez-David et al., 2017). However, it has been reported that the antidepressant-like 
effects of ketamine and the AMPA-PAM LY451646 are preserved in bdnf P+/-P heterozygous 
null mice contrary to biogenic amine-based drugs as imipramine (Lindholm et al., 2012). In 
contrast, the antidepressant-like effects of ketamine in the FST were abolished in conditional 
BDNF knockout homozygous mice (Autru et al., 2001). In our study, chronic administration 
of S 47445 reduced BDNF hippocampal expression, in parallel with the behavioral outcome, 
suggesting that the antidepressant-like effect induced by the compound would have 
compensated the dysregulation observed in the hippocampus of the OB mice. Chronic 
administration of fluoxetine did not modify BDNF expression in the hippocampus of OB 
mice, while a tendency to increase BDNF expression was observed in the prefrontal cortex, as 
















hippocampal BDNF expression is in contrast to Freitas´ study (Freitas et al., 2013). These 
discrepancies may be due to differences in the mouse strain and/or the gender (Freitas et al., 
2013). It has been shown that some antidepressant-like effects of fluoxetine may be mediated 
through a neurogenesis non-dependent mechanism (David et al., 2009), which could also 
explain the lack of effect of this antidepressant on BDNF expression that we observe in our 
study. 
In the present study, changes in phospho-mTOR and the ratio p-mTOR/mTOR in the 
hippocampus of OB mice were parallel to those observed for BDNF expression, which may 
be due to the direct correlation between both pathways (Autry et al., 2001; Duman et al., 
2012). It is worth to mention that the chronic administration of S 47445 did not alter the 
expression of mTOR in the prefrontal cortex, as it has been reported for clinically used 
antidepressants (Liu et al., 2015). Regarding 4EBP1 hippocampal expression in OB mice, 
though the ratio phosphorylated/non-phosphorylated protein is not modified, both forms of 
4EBP1 showed a clear tendency to the increase. In addition, a significant increment of the 
expression of both 4EBP1 and its phosphorylated forms was observed in OB mice treated 
with S 47445, though the ratio was unchanged. Although mTOR was not modified by the 
drug treatment, the phosphorylation of 4EBP1 is also induced by other signaling pathways as 
PI3K-Akt (Gingras et al., 1998; Kohn et al., 1998), ERK1/2 (Herbert et al., 2002), etc. This 
increase may be due to an attempt to maintain a correct transcription level, since the non-
phosphorylated 4EBP1 acts as a repressor of the protein eukaryotic translation initiation factor 
(eIF) (Gringras et al., 1999). Moreover, previous studies suggest that the fast-acting 
antidepressant-like effects of ketamine are mediated by changes in the phosphatidylinositol 3-
kinase (PI3K), Akt (protein kinase B, PKB), glycogen synthesis kinase 3 (GSK3), mammalian 
target of rapamycin (mTOR) and brain derived neurotrophic factor (BDNF) signaling 
















mood-related disorders (Liu et al., 2013; Abelaira et al., 2014; Park et al., 2014; Zhou et al., 
2014). Moreover, studies in primary hippocampal cultures demonstrate the modulation of 
mTOR pathway by glutamatergic-, but not serotonergic-related antidepressants (Zhou et al., 
2014). Regarding the modulation of mTOR signaling by fluoxetine treatment, recent studies 
report a lack of changes of this signaling pathway in hippocampus (Park et al., 2014; Liu et 
al., 2015), and in prefrontal cortex (Liu et al., 2015), in line with our findings. It should be 
considered that antidepressant-like effects of fluoxetine may be due not only to the 
modulation of neuroplasticity-related signaling pathways, but also to its capacity to modulate 
relevant neurotransmitter systems as the serotonergic (Riad et al., 2017) and the 
endocannabinoid (Rodríguez-Gaztelumendi et al., 2009) ones. Thus, the action of S 47445 on 
brain BDNF/mTOR/4EBP1signaling pathway in hippocampus could be related to its 
antidepressant-like effect in the OB model, and it appears to be distinctive to fluoxetine that 




In conclusion, all the above findings demonstrate that S 47445 induces an anxiolytic effect 
after short-term administration, and antidepressant-like effects after chronic administration in 
the OB model of depression. These changes appear to be associated to a modulation of the 
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